CorMedix (NASDAQ: CRMD) reported Q1 EPS of $0.43, $0.02 worse than the analyst estimate of $0.45. Revenue for the quarter came in at $127.43 million versus the consensus estimate of $105.02 million.

GUIDANCE:

CorMedix sees FY2026 revenue of $325-345 million, versus the consensus of $308.2 million.

For earnings history and earnings-related data on CorMedix (CRMD) click here.